GDC-0810 (ARN-810) - CAS 1365888-06-7
Catalog number: 1365888-06-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H20ClFN2O2
Molecular Weight:
446.91
COA:
Inquire
Targets:
Estrogen Receptor/ERR
Description:
GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts.
Purity:
98%
Appearance:
Solid powder
Synonyms:
GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046.
Solubility:
Soluble in DMSO, not in water
Storage:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years if stored properly
Canonical SMILES:
O=C(O)/C=C/C1=CC=C(C=C1)/C(C2=CC3=C(NN=C3)C=C2)=C(CC)\C4=CC=C(C=C4Cl)F
1.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R;Zhao J;Gutgesell LM;Wang Y;Lee S;Karumudi B;Zhao H;Lu Y;Tonetti DA;Thatcher GR J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with 2 (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to 2 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to that with 2.
2.Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A;Kahraman M;Govek S;Nagasawa J;Bonnefous C;Julien J;Douglas K;Sensintaffar J;Lu N;Lee KJ;Aparicio A;Kaufman J;Qian J;Shao G;Prudente R;Moon MJ;Joseph JD;Darimont B;Brigham D;Grillot K;Heyman R;Rix PJ;Hager JH;Smith ND J Med Chem. 2015 Jun 25;58(12):4888-904. doi: 10.1021/acs.jmedchem.5b00054. Epub 2015 May 22.
Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized. The lead compound 11l (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Estrogen Receptor/ERR Products


CAS 979-32-8 Estradiol valerate

Estradiol valerate
(CAS: 979-32-8)

Estradiol valerate is a synthetic ester, specifically the 17-pentanoyl ester, of the natural estrogen, 17β-estradiol. It was introduced in the 1950s, and a...

CAS 1111084-78-6 FERb 033

FERb 033
(CAS: 1111084-78-6)

FERb 033 is a potent and selective ERβ receptor agonist (Ki = 7.1 nM, EC50 = 4.8 nM) with 62-fold selectivity for ERβ over ERα.

CAS 1845-11-0 Nafoxidine

Nafoxidine
(CAS: 1845-11-0)

Nafoxidine, a triphenylethylene nonsteroidal agent, is a partial estrogen antagonist.

CAS 1847-63-8 Nafoxidine HCl

Nafoxidine HCl
(CAS: 1847-63-8)

Nafoxidine HCl is the hydrochloride salt of nafoxidine. Nafoxidine, structurally related to Tamoxifen, is a non-steroidal partial estrogen antagonist.

CAS 56-53-1 Diethylstilbestrol

Diethylstilbestrol
(CAS: 56-53-1)

Diethylstilbestrol, a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders.

CAS 1446712-19-1 SNG-1153

SNG-1153
(CAS: 1446712-19-1)

SNG-1153, derived from icaritin which is purified from Epimedium Genus, modulates ER-α36 and induces β-catenin phosphorylation and then down-regulates β-catenin...

CAS 57-63-6 Ethinyl Estradiol

Ethinyl Estradiol
(CAS: 57-63-6)

Ethinyl Estradiol is a derivative of 17β-estradiol (E2), the major endogenous estrogen in humans. EE2 is an orally bioactive estrogen used in many formulations ...

CAS 1365888-06-7 GDC-0810 (ARN-810)

GDC-0810 (ARN-810)
(CAS: 1365888-06-7)

GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-re...

CAS 190791-29-8 Lasofoxifene tartrate

Lasofoxifene tartrate
(CAS: 190791-29-8)

Lasofoxifene tartrate is the tartrate salt form of Lasofoxifene. Lasofoxifene is a third-generation selective estrogen receptor modulators (SERMs).

CAS 152-43-2 Quinestriol

Quinestriol
(CAS: 152-43-2)

Quinestriol, also called as Estrovis, is an orally active, long-acting, synthetic estrogen that is effective in hormone replacement therapy.

CAS 263717-53-9 PPT

PPT
(CAS: 263717-53-9)

PPT, also known as Propyl pyrazole triol, is an ERα selective agonist with a 410-fold relative binding affinity for ERα (49%) versus ERβ (0.12%) and therefore a...

CAS 7599-79-3 trans-Clomiphene Citrate

trans-Clomiphene Citrate
(CAS: 7599-79-3)

Enclomiphene citrateis a non-steroidal estrogen receptor antagonist. It can be used for secondary hypogonadism in overweight men wishing to restore normal testi...

CAS 529-59-9 Genistin

Genistin
(CAS: 529-59-9)

Genistin is a derivative of Genistein, which is a PTK inhibitor. Genistin acts as a selective estrogen receptor modulator (SERM). It increases growth of breast ...

CAS 198481-33-3 Bazedoxifene acetate

Bazedoxifene acetate
(CAS: 198481-33-3)

Bazedoxifene acetate, also called as TSE424 or WAY-140424, with antiosteoporotic it is a selective nonsteroidal estrogen receptor modulator (SERM) (ERα: IC50= 2...

CAS 56632-39-4 BHPI

BHPI
(CAS: 56632-39-4)

BHPI is an antagonist of estrogen receptor α (ERα), for it elicits sustained ERα-dependent activation of the endoplasmic reticulum (EnR) stress sensor.

CAS 2624-43-3 Cyclofenil

Cyclofenil
(CAS: 2624-43-3)

Cyclofenil is a weak non-steroidal selective estrogen receptor modulator (SERM) with ovulation induction properties. It shows higher affinity for estrogen recep...

CAS 722533-56-4 Elacestrant

Elacestrant
(CAS: 722533-56-4)

Elacestrant, also referred to RAD1901, is a selective and orally available estrogen receptor (ERR) degrader (IC50= 48 and 870 nM for ERα and ERβ, respectively) ...

CAS 198481-32-2 Bazedoxifene

Bazedoxifene
(CAS: 198481-32-2)

Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.

CAS 138090-06-9 (R,R)-THC

(R,R)-THC
(CAS: 138090-06-9)

(R,R)-THC is a non-steroidal and selective estrogen receptor ligand. (R,R)-THC exhibits agonist activity at ERα receptor (Ki = 9.0 nM) and antagonist activity a...

CAS 524684-52-4 ERB-041

ERB-041
(CAS: 524684-52-4)

ERB 041 is a highly selective agonist of the ERβ subtype of the estrogen receptor, displays >200-fold selectivity for ERβ over Erα.

Chemical Structure

CAS 1365888-06-7 GDC-0810 (ARN-810)

Quick Inquiry

Verification code

Featured Items